장마감
로그인 회원가입
CRMD
CRMD
CorMedix Inc
7월 27일 4:00 PM ET (한국 7/28 05:00)
$7.60
-0.27 ▼ -3.43%
🌙 7월 27일 7:34 PM ET (한국 7/28 08:34)
$7.67
+0.07 ▲ +0.92%

코르메드릭스(CRMD) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$596M
스몰캡
P/E
3.6
저평가 구간
배당수익률
없음
52주 위치
17%
저점 +24% · 고점 -49%
애널리스트
적극 매수
C+
Fundamental health
vs. Biotechnology 소형주
수익성 ⓘ
Top 8%
성장 ⓘ
Top 50%
밸류에이션 ⓘ
Top 81%
재무 안정 ⓘ
Top 48%
💰 Is this stock pricier than usual right now? ⓘ
Compared to this company's own recent 1년 (not other companies).
Very cheap
Cheap
Typical
Pricey
Very pricey
Simply put — what you pay today to own $1 of this company's yearly earnings is 3원. Over the past 1년, it usually traded around 4원. On the cheaper side versus its own history.
Pricy doesn't mean bad — it means expectations are already baked in.· based on 1.1 profitable years
Index ⓘ RUTP/E ⓘ 3.62EPS (ttm) ⓘ 2.1Insider Own ⓘ 7.88%Shs Outstand ⓘ 78.4MPerf Week ⓘ -2.31%
Market Cap ⓘ 0.60BForward P/E ⓘ 86.36EPS next Y ⓘ -82.54%Insider Trans ⓘ -Shs Float ⓘ 72.3MPerf Month ⓘ -1.55%
Enterprise Value ⓘ 0.56BPEG ⓘ -EPS next Q ⓘ 0.24Inst Own ⓘ 53.36%Short Float ⓘ 21.24%Perf Quarter ⓘ 2.43%
Income ⓘ 0.18BP/S ⓘ 1.49EPS this Y ⓘ -75.29%Inst Trans ⓘ -3.6%Short Ratio ⓘ 11.78Perf Half Y ⓘ 4.54%
Sales ⓘ 0.40BP/B ⓘ 1.36EPS next 5Y ⓘ -ROA ⓘ 37.51%Short Interest ⓘ 15.35MPerf YTD ⓘ -34.65%
Book/sh ⓘ 5.57P/C ⓘ 3.34EPS past 3/5Y ⓘ -ROE ⓘ 65.59%52W High ⓘ -49.2% ($14.96)Perf Year ⓘ -33.86%
Cash/sh ⓘ 2.28P/FCF ⓘ 3.06Sales past 3/5Y ⓘ 1582.83% 319.75%ROIC ⓘ 31.11%52W Low ⓘ 24.08% ($6.12)Perf 3Y ⓘ 89.05%
Dividend Est. ⓘ -EV/EBITDA ⓘ 2.57EPS Y/Y TTM ⓘ 883.51%Gross Margin ⓘ 85.83%Volatility(W/M) ⓘ 5.49% 4.86%Perf 5Y ⓘ 24.59%
Dividend TTM ⓘ -EV/Sales ⓘ 1.41Sales Y/Y TTM ⓘ 384.6%Oper. Margin ⓘ 48.41%ATR (14) ⓘ 0.38Perf 10Y ⓘ 1.33%
Dividend Ex-Date ⓘ -Quick Ratio ⓘ 2.74EPS Q/Q ⓘ 38.69%Profit Margin ⓘ 45.25%RSI (14) ⓘ 38.89Recom ⓘ 1
Dividend Gr. 3/5Y ⓘ -Current Ratio ⓘ 2.98Sales Q/Q ⓘ 226.05%SMA20 ⓘ -8.11% ($8.27)Beta ⓘ 1.5Target Price ⓘ $15
Payout ⓘ -Debt/Eq ⓘ 0.33Earnings ⓘ 2026/5/14SMA50 ⓘ -8.56% ($8.31)Rel Volume ⓘ 0.91Prev Close ⓘ $7.87
Employees ⓘ 191LT Debt/Eq ⓘ 0.33EPS/Sales Surpr. ⓘ 25.4% 21.38%SMA200 ⓘ -12.75% ($8.71)Avg Volume(3M) ⓘ 1.30MPrice ⓘ $7.6
IPO ⓘ 2010/5/13Option/Short ⓘ Yes/YesTrades ⓘ 9927Volume ⓘ 1,181,978Change ⓘ -3.43%
Quarterly earnings trend SEC filings · USD
24.3
24.6
24.9
25.3
25.6
25.9
25.12*
26.3
Revenue Net income 최근 분기: 매출 $127M (YoY +226%) · 순이익 $39M (YoY +87%)
* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red

📊 CorMedix Inc (CRMD) Investment Analysis

What kind of company is CorMedix Inc?

코르메드릭스(CRMD) 초고성장주
Healthcare · Biotechnology
Healthcare Stocks

🩺 CorMedix (CRMD) is a U.S. biotech company specializing in the prevention of catheter-related bloodstream infections (CRBSIs). Its flagship product, DefenCath, is a catheter lock solution that combines the antimicrobial agent taurolidine with the anticoagulant heparin, and is used to reduce the risk of infection in hemodialysis patients. CorMedix is an infection-prevention-focused company that holds the first and only antimicrobial catheter lock solution of its kind approved in the United States.

Learn more about CorMedix Inc →
Market Cap
$0.6B
Approx. KRW 0.8 trillion
⚖️ 0% of Samsung Electronics
Market Cap Rank3055
Employees191people
IPO2010/05/13
Current Price$7.60 ≈ 10,412원
📌 RUT · NASD · USA

Key Events

⏰ Upcoming events
🔔 Earnings release
The next release date has not been announced yet.
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🔔 Earnings release 2026년 5월 14일 (목) · 장 시작 전 EPS +25.4% 매출 +21.4%
🔔 Earnings release 2026년 3월 5일 (목) · 장 시작 전 EPS -80.4% 매출 +1.3%

Is it profitable?

Solid company — profitability & finances both healthy
Strong earnings and excellent financial health
Profitability — How efficiently it makes money
Operating Margin
Profit kept from selling products and services (higher is better)
48.4%
✓ 우수
My positionTop 5%
Low range Average High range
Biotechnology 소형주 Median -210.9% · Top tier
💡 일반적으로 10% 이상이면 양호, 20% 이상이면 우수
Net Margin
Share of revenue left after taxes and interest are paid
45.3%
✓ 우수
My positionTop 5%
Low range Average High range
Biotechnology 소형주 Median -187.6% · Top tier
💡 일반적으로 8% 이상이면 양호, 15% 이상이면 우수
Gross Margin
Profit after subtracting raw-material costs only (signals product competitiveness)
85.8%
✓ 양호
My positionMid-range
Low range Average High range
Biotechnology 소형주 Median 84.9% · Top 47%
💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)
ROE
Annual return earned on shareholders' equity (15%+ is strong)
65.6%
✓ 우수
My positionTop 5%
Low range Average High range
Healthcare 소형주 Median -37.5% · Top tier
💡 일반적으로 15% 이상이면 우수 (단, 부채 레버리지 효과 주의)
ROA
Annual earnings relative to total company assets
37.5%
✓ 우수
My positionTop 5%
Low range Average High range
Healthcare 소형주 Median -21.8% · Top tier
💡 일반적으로 5% 이상이면 양호, 10% 이상이면 우수
ROIC
Return generated per dollar invested in the business
31.1%
✓ 우수
My positionTop 5%
Low range Average High range
Healthcare 소형주 Median -25.0% · Top tier
💡 자본비용(보통 8~10%)보다 높으면 가치 창출, 15% 이상이면 우수
Financial health — Debt & liquidity burden
Debt-to-Equity (D/E)
Debt relative to equity (lower is healthier)
0.33
✓ Healthy debt
My positionMid-range
Low range Average High range
Biotechnology Median 0.05
💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)
Current Ratio
Liquid assets available to cover liabilities due within a year
2.98
✓ 양호
My positionMid-range
Low range Average High range
Biotechnology Median 5.75
💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의
Quick Ratio
Liquid assets excluding inventory, available for immediate use
2.74
✓ 양호
My positionMid-range
Low range Average High range
Biotechnology Median 5.47
💡 1.0 이상이면 안전, 0.5 미만이면 주의
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook
Positive and negative signals are mixed
애널리스트 목표가
$15.00
현재가 대비 +97.4%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
예상 PER (Forward)
86.36배
💡 내년 예상 EPS 기준. 현재 PER과 비교해 이익 성장 반영 정도 확인
내년 EPS 예상 성장률
-82.5%
💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

Average Earnings Performance
Mixed beats and misses
1
예상 상회
0
예상 부합
1
예상 하회
50%
상회 비율
-37.2%
평균 서프라이즈
2026.05.14
상회
실적 $0.35 · 예상 $0.33 +5.9%
2026.03.05
하회
실적 $0.16 · 예상 $0.81 -80.2%
💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Growth Expected to Slow
Historical growth is expected to lose momentum
🔮 How much will it grow? (analyst forecasts)
This Year's EPS Outlook
Projected EPS growth rate for this year
-75.3%
매우 부진
My positionBottom 5%
Low range Average High range
초고성장주 소형주 Median 51.6% · Bottom tier
Next Year's EPS Outlook
Projected EPS growth rate for next year (analyst consensus)
-82.5%
매우 부진
My positionBottom 5%
Low range Average High range
초고성장주 소형주 Median 33.7% · Bottom tier
📊 How much has it grown? (actual results)
Past 5-Year Revenue
How much revenue grew over the past 5 years
+319.8%
우수
My positionTop 5%
Low range Average High range
초고성장주 소형주 Median 32.4% · Top tier
⚡ Short-term momentum
QoQ Revenue
Revenue change from the previous quarter (short-term momentum)
+226.1%
우수
My positionTop 5%
Low range Average High range
초고성장주 소형주 Median 14.5% · Top tier
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.
New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Long-term weakness — -44%p below the market
CRMD +24.6% · S&P 500 +68.3%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
-43.8%p
Significantly behind the market
vs Health Care (XLV)
+0.1%p
roughly in line with the sector average
1-year basis
vs S&P 500
-49.9%p
Significantly behind the market
vs Health Care (XLV)
-53.6%p
Significantly behind the sector average
Rank among peers
5-year return Top 18% Based on 123 peers
1-year return Bottom 10% Based on 154 peers
Current position within 52-week range
Low (-24.1%p) High (-49.2%p)
Current price is 24.1% above the 52-week low and 49.2% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-20.3%
Annualized volatility
46.5%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔴
Current diagnosis · 2026-07-27
Downtrend zone

Current price $7.60 below the midline ($8.27). Normal downward flow. Below the Ichimoku cloud (bearish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🔴
Current diagnosis · 2026-07-27
Bearish momentum holding

MACD -0.134 < Signal -0.048 in negative zone + Hist negative (-0.086). Weakness in progress.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔴
Current diagnosis · 2026-07-27
Bearish zone

RSI 39.0 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 1.4.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Cheaper than peers in its industry
Cheap on Vs. Assets·Vs. Sales·Vs. Cash Flow, In line with peers on Vs. Earnings
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
💵 Vs. Earnings Mid-range
🏢 Vs. Assets Cheap
🧾 Vs. Sales Cheap
💧 Vs. Cash Flow Cheap
💵 Vs. Earnings
PER Price-to-Earnings Ratio
How expensive the price is vs. earnings — lower is cheaper
3.62x
✓ Very cheap
My positionTop 25%
Low range Average High range
Biotechnology 소형주 median 7.65x · Top 15% — relatively cheap within the industry
💡 PER 15 이하 저평가, 25 이상이면 성장성 검증 필요 (적자 기업은 의미 없음)
💵 Vs. Earnings
Forward PER Forward Price-to-Earnings Ratio
PER using next year's estimated earnings — reflects growth
86.36x
✓ Very pricey
My positionBottom 5%
Low range Average High range
Biotechnology 소형주 median 18.33x · Bottom 1% — expensive within the industry
💡 향후 12개월 예상 EPS 기준 PER. 현재 PER보다 낮으면 이익 성장 중
🏢 Vs. Assets
PBR Price-to-Book Ratio
Price vs. the company's asset value — below 1 trades cheaper than assets
1.36x
✓ Very cheap
My positionTop 5%
Low range Average High range
Biotechnology 소형주 median 3.34x · Top 1% — relatively cheap within the industry
💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)
🧾 Vs. Sales
PSR Price-to-Sales Ratio
Market cap vs. revenue — lower is cheaper relative to sales
1.49x
✓ Very cheap
My positionTop 5%
Low range Average High range
Biotechnology 소형주 median 14.61x · Top 1% — relatively cheap within the industry
💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)
💧 Vs. Cash Flow
EV/EBITDA Enterprise Value Multiple
Total enterprise value ÷ operating cash earnings — a benchmark for M&A
2.57x
✓ Very cheap
My positionTop 5%
Low range Average High range
Biotechnology 소형주 median 19.26x · Top 1% — relatively cheap within the industry
💡 EV/EBITDA 10 이하 저평가, 20 이상이면 고평가 (M&A 밸류 기준)
💧 Vs. Cash Flow
P/FCF Price-to-Free-Cash-Flow Ratio
Price vs. actual cash generation — lower means more efficient
3.06x
✓ Very cheap
My positionTop 5%
Low range Average High range
Biotechnology 소형주 median 14.14x · Top 1% — relatively cheap within the industry
💡 P/FCF 20 이하면 현금창출 대비 저평가 (실질 수익성 기준)
Analyst target price (reference)
$15.00 vs. current price +97.4%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Biotechnology 소형주

Who owns it?

Ownership backdrop is unfavorable
Institutional net selling -3.6% · Short interest very high 21.2% · Short interest fell -2.2%p over the last 90 days
📈 Recent trading flow (6 months)
🧑‍💼 Insiders (executives & directors)
0.0%
Insiders little change
🏦 Institutions (funds & investors)
-3.6%
Institutions net selling
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 53.4%
Adequate institutional weight
Healthcare 소형주 Median 65.6%
🧑‍💼 Insiders 7.9%
Meaningful insider stake
Healthcare 소형주 Median 17.6%
👤 Retail investors (estimated) 38.8%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
21.2%
Very high — strong short-side pressure
Healthcare 소형주 Median 11.2%
Past 90 days 📉 -2.2%p decrease
Short interest days to cover
11.8 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 78.4M주
Float (tradable shares) 72.3M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding CRMD

ETFs with the highest weightings · 10 total shown
RNIN
RNIN
Bushido Capital US SMID Cap Equity ETF
1.33%
$170M
XPH
XPH
State Street SPDR S&P Pharmaceuticals ETF
1.22%
$475M
PILL
PILL
Direxion Daily Pharmaceutical & Medical Bull 3X ETF
0.95%
$21M
SFLO
SFLO
VictoryShares Small Cap Free Cash Flow ETF
0.68%
$644M
FDLS
FDLS
Inspire Fidelis Multi Factor ETF
0.55%
$228M
* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
CRMD CRMD This Stock
$596.2M3.6 ▲1.4 ▲65.59% ▲- -3.4%
LLY
$1.13T43.1 ▼36.2 ▼107.64% ▲0.58% ▼+0.1%
JNJ
$640.9B30.8 ▼7.5 ▼25.74% ▲2.02% ▲+1.0%
ABBV
$453.9B126.7 ▼- 15221.82% ▲2.67% ▲-0.9%
UNH
$379.3B26.9 ▼3.9 ▼12.49% ▲2.16% ▲-0.7%
MRK
$323.0B36.8 ▼7.0 ▼18.97% ▲2.5% ▲-0.2%
Sector Avg-26.12.7-48.83%1.23%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen
→

Related News & Content

📖 Company overview
코메딕스(CRMD) 뭐하는 회사일까? - 주가 전망·실적·시총·관련주·본사 총정리
코메딕스(CRMD)는 항균 카테터 락 용액 데펜캐스를 앞세운 미국 감염 예방 바이오테크입니다. 혈액투석 환자 대상 매출 성장과 멜린타 인수 통한 사업 다각화로 실적·전망과 관련주가 주목받는 성장 단계 바이오테크 종목입니다.
📚 Related Investment Guides
미국주식 세금 총정리 2026 — 초보자를 위한 계산법과 절세 전략
2026년 미국주식 세금 총정리. 양도소득세 22% 계산법, 배당세 15% 원천징수, 손익통산, 절세 전략까지. 실제 금액 시뮬레이션과 세금 계산기로 내 세금을 직접 확인해보세요.

FAQ

What kind of company is 코르메드릭스(CRMD)?

코르메드릭스(CRMD) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of CRMD?

The market cap of CRMD is approximately $596M, ranking 3,055 within its sector.

What is the P/E ratio of CRMD?

CRMD has a P/E ratio of approximately 3.6x, which can be used to assess its valuation relative to the Healthcare sector average.

What is the 52-week high and low for CRMD?

CRMD has recorded a 52-week high of $14.96 and a low of $6.12.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.